IPO周报 | 必贝特科创板IPO注册生效；C1 Fund在纽交所挂牌上市

Group 1: IPO Developments - The China Securities Regulatory Commission approved the registration of Guangzhou Bibet Pharmaceutical Co., Ltd. for its initial public offering on the Sci-Tech Innovation Board, allowing the issuance of up to 90 million A-shares [3][4] - Bibet focuses on innovative drug development in oncology, autoimmune, and metabolic diseases, with a complete R&D chain from early discovery to new drug registration [4] Group 2: Product Pipeline - Bibet has six core innovative drugs in clinical trials, with two products in Phase III or critical clinical trial stages: BEBT-908 for relapsed or refractory diffuse large B-cell lymphoma and BEBT-209 for HR+/HER2- advanced breast cancer [4] - Other products in various clinical stages include BEBT-109 for non-small cell lung cancer, BEBT-260 for advanced solid tumors, BEBT-305 for moderate to severe plaque psoriasis, and BEBT-503 for diabetes with non-alcoholic fatty liver disease [4] Group 3: C1 Fund IPO - C1 Fund, the first private investment company focused on Web3 and digital asset services, has officially listed on the New York Stock Exchange, issuing 6 million shares at $10 each, raising approximately $60 million [7][8] - The fund plans to invest at least 80% of its total assets in equity and equity-linked securities of companies engaged in Web3 and digital asset services, targeting a portfolio of 30 top companies in the sector [7][8]